Jazz Pharmaceuticals plc
JAZZNasdaq
$247.53
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +113.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$16.4B
Enterprise Value
$19.9B
P/E
2250.3
P/S
3.7
P/B
3.6
EV/EBITDA
7762.6
PEG
—
FCF Yield
7.8%
Dividend Yield
—
Revenue (TTM)
$4.4B
Net Income (TTM)
$29.5M
Free Cash Flow (TTM)
$1.3B
Gross Margin
—
Operating Margin
-0.9%
Net Margin
0.7%
ROE
0.7%
ROIC
-0.4%
Debt / Equity
1.2
Net Cash
-$3.5B
Return 1Y
+115.5%
Company profile
Jazz Pharmaceuticals plc identifies, develops, commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi, Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the. treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for. adults with newly-diagn
- CEO
- Bruce C. Cozadd
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3,200
- Website
- jazzpharma.com
Management & directors
- Gala Renee DPresident & CEO
- Iannone RobertEVP, Global Head of R&D & CMO
- Johnson Philip LEVP & Chief Financial Officer
- Patil Neena MEVP & Chief Legal Officer
- Pearce SamanthaEVP, Chief Commercial Officer
- Carr PatriciaSVP, Chief Accounting Officer
- Henderson Mary ElizabethSVP, Technical Operations
- Cozadd Bruce CChairman & CEO
Roles derived from SEC Form 4 filings.
Earnings
JAZZ Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.1B↑ +19.1%
Diluted EPS$4.43↓ -391.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $378.1M | $170.3M | -$65.5M | $578.6M | $716.6M | -$430.2M |
| Net income | $238.6M | -$329.7M | -$224.1M | $414.8M | $560.1M | -$356.1M |
| Diluted EPS | $4.22 | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
| Operating cash flow | $899.6M | $778.5M | $1.3B | $1.1B | $1.4B | $1.4B |
| Free cash flow | $884.6M | $750.9M | $1.2B | $1.1B | $1.4B | $1.3B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% |
| Net margin | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.1B | $897.8M | $1.0B | $1.1B | $1.2B | $1.1B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $199.4M | $260.2M | $190.8M | -$55.9M | -$686.4M | $57.5M | $254.5M | $336.6M |
| Net income | $168.6M | $215.1M | $191.1M | -$92.5M | -$718.5M | $251.4M | $203.4M | $293.1M |
| Diluted EPS | $2.49 | $3.42 | $2.97 | -$1.52 | -$11.74 | $4.08 | $3.34 | $4.43 |
| Operating cash flow | $331.4M | $398.7M | $398.6M | $429.8M | $88.8M | $474.6M | $362.5M | $408.2M |
| Free cash flow | $324.3M | $388.0M | $385.3M | $415.9M | $75.9M | $459.4M | $345.8M | $388.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 19.5% | 24.7% | 17.5% | -6.2% | -65.6% | 5.1% | 21.2% | 31.5% |
| Net margin | 16.5% | 20.4% | 17.6% | -10.3% | -68.7% | 22.3% | 17.0% | 27.4% |
Company news
Jul 18, 2026
Jul 17, 2026
Jul 16, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | COZADD BRUCE C | Sale | 6,000 | $240.47 | $1.4M | filing |
| 2026-06-30 | GALA RENEE D· President & CEO | Tax withholding | 4,835 | $237.72 | $1.1M | filing |
| 2026-06-30 | Iannone Robert· EVP, Global Head of R&D & CMO | Tax withholding | 3,764 | $237.72 | $894,778.08 | filing |
| 2026-06-30 | Johnson Philip L· EVP & Chief Financial Officer | Tax withholding | 3,343 | $237.72 | $794,697.96 | filing |
| 2026-06-30 | Patil Neena M· EVP & Chief Legal Officer | Tax withholding | 2,678 | $237.72 | $636,614.16 | filing |
| 2026-06-30 | Pearce Samantha· EVP, Chief Commercial Officer | Tax withholding | 2,527 | $237.72 | $600,718.44 | filing |
| 2026-06-15 | Smith Mark Douglas | Sale | 1,157 | $230.55 | $266,746.35 | filing |
| 2026-06-10 | Patil Neena M· EVP & Chief Legal Officer | Sale | 1,200 | $231.83 | $278,196.00 | filing |
| 2026-06-03 | GALA RENEE D· President & CEO | Gift | 600 | $0.00 | $0.00 | filing |
| 2026-06-01 | COZADD BRUCE C | Sale | 6,000 | $235.12 | $1.4M | filing |
| 2026-05-28 | Pearce Samantha· EVP, Chief Commercial Officer | Sale | 6,907 | $235.41 | $1.6M | filing |
| 2026-05-28 | Pearce Samantha· EVP, Chief Commercial Officer | Option exercise | 6,907 | $109.45 | $755,971.15 | filing |
| 2026-05-28 | Mulligan Seamus | Option exercise | 3,415 | $138.08 | $471,543.20 | filing |
| 2026-05-28 | Patil Neena M· EVP & Chief Legal Officer | Sale | 1,192 | $236.97 | $282,468.24 | filing |
| 2026-05-22 | Winningham Rick E | Sale | 2,741 | $241.57 | $662,143.37 | filing |
| 2026-05-22 | McSharry Heather Ann | Sale | 2,000 | $241.00 | $482,000.00 | filing |
| 2026-05-22 | Winningham Rick E | Option exercise | 3,415 | $138.08 | $471,543.20 | filing |
| 2026-05-01 | COZADD BRUCE C | Sale | 6,000 | $203.33 | $1.2M | filing |
| 2026-04-01 | COZADD BRUCE C | Sale | 3,684 | $190.22 | $700,777.85 | filing |
| 2026-04-01 | COZADD BRUCE C | Sale | 2,292 | $190.94 | $437,630.58 | filing |
| 2026-04-01 | COZADD BRUCE C | Sale | 24 | $191.74 | $4,601.87 | filing |
| 2026-03-09 | Carr Patricia· SVP, Chief Accounting Officer | Sale | 1,287 | $182.94 | $235,443.78 | filing |
| 2026-03-05 | COZADD BRUCE C | Tax withholding | 15,114 | $188.69 | $2.9M | filing |
| 2026-03-05 | GALA RENEE D· President & CEO | Tax withholding | 7,065 | $188.69 | $1.3M | filing |
| 2026-03-05 | Iannone Robert· EVP, Global Head of R&D & CMO | Tax withholding | 6,209 | $188.69 | $1.2M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.